Research Data Archival, Regulatory Compliance & Intellectual Property Protection
Contact Now
Biotech organisations generate vast volumes of experimental data, assay results, genomic datasets, and Electronic Lab Notebook entries across research programmes. As projects progress or conclude, retaining this data in active research systems becomes costly and operationally burdensome, yet deletion risks permanent loss of valuable scientific records.
SMARCK archives Electronic Lab Notebook entries, raw experimental data, assay results, and research documentation in a secure, structured repository - preserving scientific records in their original state with full metadata and version history.
Research teams access historical experimental data on demand, enabling retrospective analysis, project re-evaluation, and scientific publication support. Storage costs are reduced by offloading inactive data from live research platforms, and intellectual property is preserved in a secure, traceable archive for the organisation's long-term benefit.
Biotech companies are required to retain all data underlying regulatory submissions - including INDs, BLAs, NDAs, and CTAs - in an accurate, complete, and accessible state throughout and beyond the product lifecycle. Managing this obligation across evolving research platforms and growing data volumes presents significant compliance challenges.
SMARCK provides structured archival of regulatory submission packages, supporting datasets, analytical method validations, and correspondence with health authorities - with immutable storage, full audit trail preservation, and search capabilities aligned to regulatory dossier structures.
Regulatory inspections and data integrity reviews are supported by complete, rapidly retrievable submission records. Biotech companies demonstrate robust data stewardship to health authorities, and the risk of regulatory action due to incomplete or inaccessible submission data is substantially reduced.
Biotech intellectual property portfolios are underpinned by scientific data, invention disclosures, prior art analyses, and prosecution correspondence that must be preserved securely to support patent defence, licensing negotiations, and freedom-to-operate assessments. Inadequate data protection creates significant IP and commercial risk.
SMARCK archives invention disclosures, patent prosecution records, licensing agreements, scientific evidence packages, and IP-related correspondence with encrypted, access-controlled storage and comprehensive audit logging - ensuring IP assets are protected throughout their commercial lifecycle.
Patent portfolios are supported by complete, securely archived scientific and legal records. IP teams access historical documentation efficiently for prosecution, defence, and licensing activities, and the organisation is well-positioned to demonstrate invention priority and data integrity in the event of disputes or litigation.
Biotech companies advancing assets through clinical development generate substantial volumes of GCP-regulated data - including protocol amendments, site files, patient records, and safety reports - that must be retained in compliance with applicable regulations throughout and well beyond the study period.
Biotech companies advancing assets through clinical development generate substantial volumes of GCP-regulated data - including protocol amendments, site files, patient records, and safety reports - that must be retained in compliance with applicable regulations throughout and well beyond the study period.
SMARCK provides GCP-compliant archival of clinical programme records with structured metadata, role-based access for study teams and regulatory personnel, and retention schedules aligned to ICH E6 and applicable national requirements.
SMARCK provides GCP-compliant archival of clinical programme records with structured metadata, role-based access for study teams and regulatory personnel, and retention schedules aligned to ICH E6 and applicable national requirements.
Clinical data archival obligations are fulfilled consistently and efficiently. Regulatory inspections are supported by complete, structured access to study records, and biotech organisations demonstrate the data stewardship standards required to progress assets through late-stage development and regulatory review.
Clinical data archival obligations are fulfilled consistently and efficiently. Regulatory inspections are supported by complete, structured access to study records, and biotech organisations demonstrate the data stewardship standards required to progress assets through late-stage development and regulatory review.
Next-generation sequencing, proteomics, and biomarker programmes generate exceptionally large datasets that are expensive to store in active high-performance computing environments. As research programmes evolve, the challenge of retaining raw genomic and biomarker data in an accessible, compliant manner becomes increasingly acute.
SMARCK provides scalable, cost-effective archival of genomic datasets, sequencing outputs, biomarker profiles, and associated analytical pipelines - with metadata-driven search and controlled access enabling retrieval of specific datasets without the need to restore entire archives.
Genomic and biomarker data is preserved at a fraction of the cost of active HPC storage. Research and bioinformatics teams access archived datasets on demand for retrospective analysis, companion diagnostic development, and regulatory submissions - maximising the long-term scientific and commercial value of research investments.
Biotech companies engaged in research collaborations, licensing partnerships, and co-development agreements are required to manage data sharing, segregation, and retention obligations across multiple parties. Inadequate data governance in these contexts creates legal exposure and may compromise proprietary research assets.
SMARCK provides a structured, secure data archival environment for collaboration and partnership records - including research data packages, technology transfer documentation, licensing agreements, and joint development records- with granular access controls aligned to contractual obligations.
Data governance obligations arising from research partnerships and licensing arrangements are fulfilled with precision and confidence. Partner-specific data is appropriately segregated and access-controlled, contractual compliance is maintained, and proprietary research assets are protected throughout the collaboration lifecycle.